Aktieanalys

IRLAB Q1: Multiple potential roads ahead - Redeye

{newsItem.title}

Redeye Publicerad: 12 May 07:20

IRLAB Therapeutics

Redeye provides a research update following IRLAB's Q1 report. Following the ambiguous results from the Pirepemat phase IIb study, we believe that the company's direction and prioritization regarding business development and clinical activity ahead will be crucial.

Länk till analysen i sin helhet: https://www.redeye.se/research/1099954/irlab-q1-multiple-potential-roads-ahead?utm_source=finwire&utm_medium=RSS

Nyheter om IRLAB Therapeutics

Läses av andra just nu

Om aktien IRLAB Therapeutics

Senaste nytt